Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

HBM Holdings Ltd. partners with Otsuka Pharmaceutical in a partnership valued at up to $670 million for cancer immunotherapy development.

Jul 03, 2025•12 months ago

Contract Type

partnership

St. LouisManufacturing

Description

HBM Holdings Ltd. has announced a partnership with Japan's Otsuka Pharmaceutical Co. Ltd. for a cancer drug, HBM7020, worth up to $670 million

Company Information

Company

HBM Holdings

Location

St. Louis, Missouri, United States

About

HBM Holdings is a privately held global conglomerate focused on strategically acquiring and partnering with middle-market industrial companies. HBM invests in and builds high-performing companies within mission-critical industries, including Aerospace & Defense, Environmental, Medical Devices & Instruments, and Packaging. HBM's portfolio of companies includes MLC, Schafer Industries, HarperLove, and Control Devices.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for HBM Holdings's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months